Aligos Therapeutics, Inc.ALGSNASDAQ
Loading
Operating Expenses Over TimeStable
Percentile Rank29
3Y CAGR-7.2%
5Y CAGR-1.1%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-7.2%/yr
vs +69.0%/yr prior
5Y CAGR
-1.1%/yr
Recent deceleration
Acceleration
-76.2pp
Decelerating
Percentile
P29
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
4 yr
Consecutive declineStable
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $89.24M | -4.1% |
| 2024 | $93.10M | -10.2% |
| 2023 | $103.66M | -7.0% |
| 2022 | $111.49M | -16.0% |
| 2021 | $132.68M | +40.4% |
| 2020 | $94.51M | +74.9% |
| 2019 | $54.04M | +295.6% |
| 2018 | $13.66M | - |